Innovation supply chain model risks "teaching to the test"

05/2/2013 | Xconomy

Drug development based on an "innovation supply chain" could stifle innovation if drugmakers push small biotech partners to follow a set route, writes Katrine Bosley, former CEO of Avila Therapeutics. "The more innovative the science, the more likely it is that the real challenge is to cultivate a new vision," she writes. Two-way, iterative partnerships bring together big drugmakers' experience with small biotechs' innovation, Bosley writes.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC